24 June 2019
Half yearly results for the six months ended 31 May 2019…
Disposal of Chemring Defence…
21 June 2019
Appointment of Chief Financial Officer…
Trading Update
Completion of formation of a new Joint Venture with BRAVO and acquisition…
20 June 2019
Trading Update and Statement Regarding a Possible Offer…
19 June 2019
Q1 FY20 Trading Update
18 June 2019
Lynparza approved in the EU for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer…